Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14

MLA

Bubendorf Lukas, et al. “Results of a Phase I/II Single Arm Clinical Trial Assessing Efficacy, Safety and Tolerability of the Recombinant Bacillus Calmette Guérin VPM1002BC in Patients with Non-Muscle Invasive Bladder Cancer Recurrence after BCG Induction with or without BCG Maintenance Therapy – SAKK 06/14.” Urologic Oncology: Seminars and Original Investigations, vol. 38, Dec. 2020, p. 898. EBSCOhost, https://doi.org/10.1016/j.urolonc.2020.10.027.

APA

Bubendorf Lukas, Cyrill A. Rentsch, Pedrazzini Augusto, Torpai Raimund, Hefermehl Lukas, Engeler Daniel, Roghmann Florian, Boll Daniel, Bosshard Piet, Maciej Kwiatkowski, Schultze-Seemann Wolfgang, Räto T. Strebel, Grégory Johann Wirth, Hayoz Stefanie, Püschel Heike, Roth Beat, Wicki Andreas, Hüttenbrink Clemens, Gierth Michael, … Ilaria Lucca. (2020). Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14. Urologic Oncology: Seminars and Original Investigations, 38, 898. https://doi.org/10.1016/j.urolonc.2020.10.027

Chicago

Bubendorf Lukas, Cyrill A. Rentsch, Pedrazzini Augusto, Torpai Raimund, Hefermehl Lukas, Engeler Daniel, Roghmann Florian, et al. 2020. “Results of a Phase I/II Single Arm Clinical Trial Assessing Efficacy, Safety and Tolerability of the Recombinant Bacillus Calmette Guérin VPM1002BC in Patients with Non-Muscle Invasive Bladder Cancer Recurrence after BCG Induction with or without BCG Maintenance Therapy – SAKK 06/14.” Urologic Oncology: Seminars and Original Investigations 38 (December): 898. doi:10.1016/j.urolonc.2020.10.027.